BSE has listed 72,50,000 new equity shares of Sarda Proteins Ltd (Scrip Code: 519242) effective Tuesday, May 12, 2026. The shares were issued at Rs. 115/- each (face value Rs. 10/- + premium Rs. 105/-) to Promoters and Non-Promoters on a preferential basis pursuant to conversion of warrants. These shares rank pari-passu with the existing equity shares of the company.

Key Points

• 72,50,000 equity shares of Rs. 10/- face value issued at Rs. 115/- (Rs. 105/- premium) via preferential allotment
• Allotment was made to both Promoter and Non-Promoter categories through conversion of warrants
• Distribution numbers: 1725901 to 8975900
• Date of allotment: March 18, 2026
• ISIN: INE995U01011
• Shares are pari-passu with existing equity shares
• Trading permitted from May 12, 2026

Regulatory Changes

No new regulatory changes introduced. This is a standard listing notice under BSE’s Listing Operations framework for newly allotted securities.

Compliance Requirements

• Trading members are informed to permit trading of the newly listed shares from May 12, 2026
• Lock-in restrictions must be observed by holders of the locked-in shares as per the details below

Important Dates

• Date of Allotment: March 18, 2026
• Effective Trading Date: May 12, 2026 (Tuesday)
• Lock-in Expiry (72,20,000 shares): November 17, 2027 — Distribution Nos. 1725901 to 8945900
• Lock-in Expiry (30,000 shares): November 17, 2026 — Distribution Nos. 8945901 to 8975900

Impact Assessment

The listing adds 72,50,000 new shares to Sarda Proteins Ltd’s equity base, expanding the total outstanding share count. However, the near-total lock-in (72,20,000 out of 72,50,000 shares locked until November 2027) significantly limits immediate free-float impact. Only 30,000 shares are subject to the shorter lock-in expiring November 2026. The preferential allotment at Rs. 115/- per share reflects the company’s capital-raising activity through warrant conversion, which may signal ongoing business expansion or debt restructuring.